Congenital Adrenal Hyperplasia Clinical Trials

79 clinical trials for Congenital Adrenal Hyperplasia across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) — RECRUITING · PHASE2
• A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia — RECRUITING · PHASE3
• Natural History Study of Patients With Excess Androgen — RECRUITING
• An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia — RECRUITING · PHASE2
• Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC) — RECRUITING
• A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia — RECRUITING · PHASE1
• Institutional Registry of Rare Diseases — RECRUITING
• Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment — RECRUITING · PHASE4
• Fertility And Sexual Function In CAH: CALLIOPE — RECRUITING
• Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency — RECRUITING
• GROWing Up With Rare GENEtic Syndromes — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN PEDIATRIC SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT — RECRUITING
• Evaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia — NOT_YET_RECRUITING
• Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia — NOT_YET_RECRUITING
• A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia — TERMINATED · PHASE2
• An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants with Congenital Adrenal Hyperplasia — TERMINATED · PHASE2
• Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia — COMPLETED · PHASE3
• Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT - — TERMINATED · PHASE2
• AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY OF ATUMELNANT IN PARTICIPANTS WITH CONGENITAL ADRENAL HYPERPLASIA — NOT_YET_RECRUITING
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia — ACTIVE_NOT_RECRUITING · PHASE3
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old — NOT_YET_RECRUITING · PHASE2
• Retrospective Multicentre Study on the Impact of Neonatal Screening for Congenital Adrenal Hyperplasia in Italy — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATUMELNANT IN ADULT PARTICIPANTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA — NOT_YET_RECRUITING
• A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH — TERMINATED · PHASE2
• A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) — ACTIVE_NOT_RECRUITING · PHASE1
• Prenatal Dex Study — COMPLETED · NA
• A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia — WITHDRAWN · NA
• Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 — TERMINATED · PHASE1
• Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia — COMPLETED · PHASE2
• A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH — TERMINATED · PHASE2
• Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) — COMPLETED · PHASE2
• Investigation of the Etiology of Hypertension and Endothelial Damage in Patients With Cytochrome P450 Oxidoreductase Deficiency — COMPLETED
• Baby Detect : Genomic Newborn Screening — COMPLETED
• Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH — COMPLETED
• A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH — TERMINATED · PHASE2
• Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia — COMPLETED · PHASE1
• Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia — COMPLETED · PHASE3
• Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia — COMPLETED · PHASE2
• Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia — COMPLETED · PHASE3
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH — COMPLETED · PHASE3
• A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181]) — COMPLETED
• Testicular Adrenal Rest Tumor in Congenital Adrenal Hyperplasia Patients Attending Assuit University Children Hospital — NOT_YET_RECRUITING
• Study of UK Adults With Congenital Adrenal Hyperplasia. — COMPLETED
• Decision Support for Parents Receiving Information About Child's Rare Disease — COMPLETED
• Dynamic Hormone Diagnostics in Endocrine Disease — COMPLETED
• Growing up With the Young Endocrine Support System (YESS!) — NOT_YET_RECRUITING · NA
• Androgen Reduction in Congenital Adrenal Hyperplasia — WITHDRAWN · PHASE2
• Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia — COMPLETED

Refine this search